244 related articles for article (PubMed ID: 34357463)
1. Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis.
Sinto MS; Thomas S; Kannan S
Med Oncol; 2021 Aug; 38(9):110. PubMed ID: 34357463
[TBL] [Abstract][Full Text] [Related]
2. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling.
Pidugu VK; Wu MM; Yen AH; Pidugu HB; Chang KW; Liu CJ; Lee TC
Oncogene; 2019 Apr; 38(17):3232-3247. PubMed ID: 30626937
[TBL] [Abstract][Full Text] [Related]
3. FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.
Bernat-Peguera A; Navarro-Ventura J; Lorenzo-Sanz L; da Silva-Diz V; Bosio M; Palomero L; Penin RM; Pérez Sidelnikova D; Bermejo JO; Taberna M; Vilariño N; Piulats JM; Mesia R; Viñals JM; González-Suárez E; Capella-Gutierrez S; Villanueva A; Viñals F; Muñoz P
Clin Cancer Res; 2021 Mar; 27(5):1491-1504. PubMed ID: 33262138
[TBL] [Abstract][Full Text] [Related]
4. Baicalein inhibits the growth of oral squamous cell carcinoma cells by downregulating the expression of transcription factor Sp1.
Gao Z; Zhang Y; Zhou H; Lv J
Int J Oncol; 2020 Jan; 56(1):273-282. PubMed ID: 31746368
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
6. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
7. Neuropilin-1 promotes epithelial-to-mesenchymal transition by stimulating nuclear factor-kappa B and is associated with poor prognosis in human oral squamous cell carcinoma.
Chu W; Song X; Yang X; Ma L; Zhu J; He M; Wang Z; Wu Y
PLoS One; 2014; 9(7):e101931. PubMed ID: 24999732
[TBL] [Abstract][Full Text] [Related]
8. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
9. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
10. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis.
Sasabe E; Tomomura A; Liu H; Sento S; Kitamura N; Yamamoto T
Cancer Sci; 2022 Feb; 113(2):609-621. PubMed ID: 34874595
[TBL] [Abstract][Full Text] [Related]
12. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
13. Propofol induces apoptosis and ameliorates 5‑fluorouracil resistance in OSCC cells by reducing the expression and secretion of amphiregulin.
Yang KS; Che PC; Hsieh MJ; Lee IN; Wu YP; Chen MS; Chen JC
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34859260
[TBL] [Abstract][Full Text] [Related]
14. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
Zhu R; Mao Y; Xu X; Li Y; Zheng J
Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
[TBL] [Abstract][Full Text] [Related]
15. [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
Gong H; Yuan Y; Li Y; Zhang H; Li Y; Li W; Wang P; Shi R; Liu C; Cui L; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):255-263. PubMed ID: 31109434
[TBL] [Abstract][Full Text] [Related]
16. WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway.
Zhang X; Sun K; Gan R; Yan Y; Zhang C; Zheng D; Lu Y
BMC Cancer; 2024 May; 24(1):564. PubMed ID: 38711026
[TBL] [Abstract][Full Text] [Related]
17. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
18. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Rose M; Maurer A; Wirtz J; Bleilevens A; Waldmann T; Wenz M; Eyll M; Geelvink M; Gereitzig M; Rüchel N; Denecke B; Eltze E; Herrmann E; Toma M; Horst D; Grimm T; Denzinger S; Ecke T; Vögeli TA; Knuechel R; Maurer J; Gaisa NT
Oncogene; 2020 Oct; 39(44):6856-6870. PubMed ID: 32978523
[TBL] [Abstract][Full Text] [Related]
19. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
Sasabe E; Tomomura A; Yamamoto T
J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
[TBL] [Abstract][Full Text] [Related]
20. Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.
Chang JW; Kang SU; Shin YS; Seo SJ; Kim YS; Yang SS; Lee JS; Moon E; Lee K; Kim CH
Sci Rep; 2015 Dec; 5():18208. PubMed ID: 26655729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
